Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
- Conditions
- Cryopyrin-Associated Periodic SyndromesAmyloidosis
- Interventions
- Drug: 124I AT-01
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-21
- Target Recruit Count
- 30
- Registration Number
- NCT06974877
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Base Editing Hematopoietic Stem Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study
- Conditions
- CD40L-HyperIgM Syndrome
- Interventions
- Biological: Base-edited hematopoietic stem and progenitor cells
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-21
- Target Recruit Count
- 1
- Registration Number
- NCT06959771
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-05-20
- Target Recruit Count
- 51
- Registration Number
- NCT06945276
- Locations
- 🇺🇸
Dr. Vince Clinical Research, Overland Park, Kansas, United States
A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1-RNA in Adults Without HIV
- Conditions
- HIV-1-infection
- Interventions
- Biological: DV700P-RNABiological: DV701B1.1-RNA
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Target Recruit Count
- 45
- Registration Number
- NCT06919016
- Locations
- 🇺🇸
University of Alabama Medical Center (Site ID: 31788), Birmingham, Alabama, United States
🇺🇸Hope Clinic (Site ID: 31440), Decatur, Georgia, United States
🇺🇸Columbia University Medical Center (Site ID: 10032), New York, New York, United States
Treatment of Antibody-Mediated Rejection (ABMR) With CarBel
- Conditions
- Kidney Transplant Rejection
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Target Recruit Count
- 100
- Registration Number
- NCT06918990
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)
- Conditions
- Kidney Transplant
- Interventions
- Other: Placebo for Berinert
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Target Recruit Count
- 180
- Registration Number
- NCT06919003
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
- Conditions
- EBVEpstein-Barr Virus InfectionInfectious MononucleosisMono
- Interventions
- Biological: EBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvantBiological: EBV gp350-ferritin vaccine with ALFQ adjuvant
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-05-21
- Target Recruit Count
- 750
- Registration Number
- NCT06908096
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART
- Conditions
- HIV
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-05-21
- Target Recruit Count
- 50
- Registration Number
- NCT06908083
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸Rockefeller Institute, New York, New York, United States
A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Target Recruit Count
- 25
- Registration Number
- NCT06905275
- Locations
- 🇺🇸
University of Alabama - Birmingham, Birmingham, Alabama, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
🇺🇸Columbia University, New York, New York, United States
Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
- Conditions
- HIV
- Interventions
- Biological: HxB2.WT.Core-C4bBiological: 3M-052-AF adjuvantOther: Aluminum hydroxide suspension (Alum) adjuvantOther: Diluent
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-27
- Target Recruit Count
- 42
- Registration Number
- NCT06796686
- Locations
- 🇺🇸
Bridge HIV, San Francisco Department of Public Health, San Francisco, California, United States
🇺🇸Ponce de Leon Center CRS, Atlanta, Georgia, United States
🇺🇸The Hope Clinic of the Emory Vaccine Research Center; Emory University, Decatur, Georgia, United States